(19)
(11) EP 4 798 223 A2

(12)

(88) Date of publication A3:
12.06.2025

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24883408.7

(22) Date of filing: 25.10.2024
(51) International Patent Classification (IPC): 
A61K 38/17(2006.01)
C12N 15/86(2006.01)
C07K 14/71(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 2770/36143; A61K 48/0016; A61K 48/0041; C12N 15/88; C07K 14/71
(86) International application number:
PCT/US2024/052996
(87) International publication number:
WO 2025/090889 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 27.10.2023 US 202363593800 P

(71) Applicant: Replicate Bioscience, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • WANG, Nathaniel Stephen
    San Diego, California 92121 (US)
  • MAINE, Christian
    San Diego, California 92121 (US)
  • ALIAHMAD, Parinaz
    San Diego, California 92121 (US)
  • MIYAKE-STONER, Shigeki Joseph
    San Diego, California 92121 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) COMPOSITIONS AND METHODS FOR EXPRESSION OF EGFR